Use of an IL1‐receptor antagonist to prevent the progression of tendinopathy in a rat model. Issue 4 (29th December 2015)

• Record Type: Journal Article
• Authors: Berkoff, David J.; Kallianos, Steven A.; Eskildsen, Scott M.; Weinhold, Paul S.
• Is Part Of: Journal of orthopaedic research. Volume 34:Issue 4(2016)
• Page Start: 616
• Page End: 622
• Publication Date: 2015-12-29
• Subjects: inflammatory cytokine -- patellar tendon -- IL1 -- carrageenan -- tendon inflammation; Orthopedics -- Periodicals; Musculoskeletal system -- Periodicals; 616.7
• DOI: 10.1002/jor.23057
• Languages: English
• ISSNs: 0736-0266

Abstract

ABSTRACT: This study evaluated if inhibiting IL1‐β activity with an IL1‐receptor antagonist (IL1‐RA) will prevent pathologic changes commonly seen in tendinopathy. Thirty‐six Sprague–Dawley retired‐breeder rats were divided into three groups having weekly bilateral patellar tendon injections: CON (0.1 ml Saline), CAR (0.1 ml 2% carrageenan), IL1‐RA (0.1 ml 2% CAR plus 0.94 mg of the IL1‐RA, 2.5 mg/kg). Carrageenan was used to establish tendinopathy in two groups due to its ability to develop tendinopathy in prior studies. Animals were euthanized 3 weeks after initial injection. The CAR group demonstrated significantly ( p < 0.05) shorter tendon lengths (8.61 ± 0.38 mm) relative to CON (8.94 ± 0.38 mm) that was prevented in the IL1‐RA (9.02 ± 0.30 mm) as well as significantly increased collagenase activity in the CAR (0.061 ± 0.043) compared to CON (0.027 ± 0.015) ( p < 0.05). By histological evaluation, the CAR group demonstrated significantly greater inflammation than IL1‐RA, and CON ( p < 0.05). CAR showed a trend for increased cross‐sectional area relative to CON that was absent in the IL1‐RA. IL1‐RA can effectively inhibit the development of mechanical, chemical, and histologic changes seen with carrageenan‐induced tendonitis. © 2015 Orthopaedic Research Society. Published by Wiley Periodicals, Inc. J Orthop Res 34:616–622, 2016.